These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 14642559)

  • 1. Characteristics and prognosis of hepatocellular carcinoma detected in sustained responders to interferon therapy for chronic hepatitis C.
    Toyoda H; Kumada T; Hayashi K; Honda T; Morita K; Nishimura D; Imada K; Imoto M; Horiguchi Y; Nakano H; Nakano I; Fukuda Y;
    Cancer Detect Prev; 2003; 27(6):498-502. PubMed ID: 14642559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Tokuda A; Horiguchi Y; Nakano H; Honda T; Nakano S; Hayashi K; Katano Y; Nakano I; Hayakawa T; Nishimura D; Kato K; Imada K; Imoto M; Fukuda Y;
    J Viral Hepat; 2000 Nov; 7(6):414-9. PubMed ID: 11115052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
    Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
    J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Honda T; Hayashi K; Katano Y; Nakano I; Hayakawa T; Fukuda Y
    J Gastroenterol Hepatol; 2001 Oct; 16(10):1131-7. PubMed ID: 11686840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders.
    Sou FM; Wu CK; Chang KC; Lu SN; Wang JH; Hung CH; Chen CH; Kee KM; Yen YH; Lin MT; Tsai MC; Hu TH
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):504-513. PubMed ID: 30527565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma.
    Shirabe K; Sugimachi K; Harada N; Kayashima H; Maeda T; Tsujita E; Minagawa R; Kajiyama K; Yoshiya S; Maehara Y
    Anticancer Res; 2015 Dec; 35(12):6963-9. PubMed ID: 26637923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.
    Omata M; Yoshida H; Shiratori Y
    Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S141-3. PubMed ID: 16234063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
    Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
    Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.
    Yoshida H; Tateishi R; Arakawa Y; Sata M; Fujiyama S; Nishiguchi S; Ishibashi H; Yamada G; Yokosuka O; Shiratori Y; Omata M
    Gut; 2004 Mar; 53(3):425-30. PubMed ID: 14960528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma.
    Tsujita E; Maeda T; Kayashima H; Harada N; Tsutsui S; Matsuda H; Kinjo N; Ikeda Y; Morita M; Ishida T
    Hepatogastroenterology; 2015; 62(137):157-63. PubMed ID: 25911888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma.
    Miyatake H; Kobayashi Y; Iwasaki Y; Nakamura S; Ohnishi H; Kuwaki K; Toshimori J; Hagihara H; Nouso K; Yamamoto K
    Dig Dis Sci; 2012 Apr; 57(4):1092-101. PubMed ID: 21989822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy.
    Okanoue T; Minami M; Makiyama A; Sumida Y; Yasui K; Itoh Y
    Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S89-91. PubMed ID: 16234069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second hepatectomy for recurrent hepatocellular carcinoma achieved sustained virological response to interferon therapy for hepatitis C.
    Tsujita E; Yamashita Y; Takeishi K; Maeda T; Takaki S; Mori N; Aisaka Y; Furukawa Y; Shirabe K; Ishida T; Maehara Y
    Hepatogastroenterology; 2013; 60(128):2048-54. PubMed ID: 24088310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
    Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
    Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus.
    Hung CH; Lee CM; Wang JH; Tung HD; Chen CH; Lu SN
    J Gastroenterol Hepatol; 2005 Oct; 20(10):1553-9. PubMed ID: 16174073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two Cases of Hepatocellular Carcinoma Arising Over 20 Years after a Sustained Virologic Response Following Interferon Therapy for Chronic Hepatitis C.
    Takata K; Ishii F; Uchida Y; Fukuda H; Yamauchi R; Umeda K; Tsuchiya N; Tanaka T; Yokoyama K; Morihara D; Takeyama Y; Shakado S; Sakisaka S; Hirai F
    Intern Med; 2020 Aug; 59(15):1855-1860. PubMed ID: 32350199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C.
    Na SK; Song BC
    Clin Mol Hepatol; 2019 Sep; 25(3):234-244. PubMed ID: 30661334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy.
    Nagaoki Y; Aikata H; Miyaki D; Murakami E; Hashimoto Y; Katamura Y; Azakami T; Kawaoka T; Takaki S; Hiramatsu A; Waki K; Imamura M; Kawakami Y; Takahashi S; Chayama K
    J Gastroenterol; 2011 Jun; 46(6):799-808. PubMed ID: 21373851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.